Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate

Journal of Bone and Mineral Research

Volumn 19, Issue 5, 2004, Pages 745-751

  Ettinger, Bruce ^a   San Martin, Javier ^b   Crans, Gerald ^b   Pavo, Imre ^b  

^a DIVISION OF RESEARCH   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Bisphosphonates; Osteoporosis; Parathyroid hormone; Selective estrogen receptor modulators

Indexed keywords

ALENDRONIC ACID; CALCIUM; PARATHYROID HORMONE[1-34]; RALOXIFENE; VITAMIN D; ALKALINE PHOSPHATASE; BIOLOGICAL MARKER; COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS LINKED PEPTIDE; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; OSTEOCALCIN; PARATHYROID HORMONE; PEPTIDE;

ADULT; AGED; ARTICLE; BONE DENSITOMETRY; BONE DENSITY; BONE TURNOVER; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; FEMALE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; OSTEOPOROSIS; POSTMENOPAUSE; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION; BLOOD; CLINICAL TRIAL; DRUG INTERACTION; HIP; LONGITUDINAL STUDY; LUMBAR VERTEBRA; METABOLISM; MIDDLE AGED; POSTMENOPAUSE OSTEOPOROSIS; RADIOGRAPHY;

AGED; AGED, 80 AND OVER; ALENDRONATE; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE DENSITY; COLLAGEN; COLLAGEN TYPE I; DRUG INTERACTIONS; FEMALE; HIP; HUMANS; LONGITUDINAL STUDIES; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOCALCIN; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; PEPTIDES; RALOXIFENE; TERIPARATIDE;

EID: 3242762388     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/JBMR.040117     Document Type: Article

References (27)

1. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441.
2. Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster D, Cosman F 1997 Randomized controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350:550-555.
3. Cosman F, Nieves J, Woelfert L, Formica C, Gordon S, Shen V, Lindsay R 2001 Parathyroid hormone added to established hormone therapy: Effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 16:925-931.
4. Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, Shane E, Plavetic K, Muller R, Bilezikian J, Lindsay R 2001 Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: A paired biopsy study. J Bone Miner Res 16:1846-1853.
5. Lane NE, Sanchez S, Modin GW, Genant UK, Pierini E, Arnaud CD 1998 Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 102:1627-1633.
6. Cosman F, Nieves J, Woelfert L, Shen V, Lindsay R 1998 Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women. J Bone Miner Res 13:1051-1055.
7. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ 2003 The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207-1215.
8. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM 2003 The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349:1216-1226.
9. IMS Health 2002 National prescriptions audit. Available online at http://imshealth.com.
10. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ 1997 Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100:1475-1480.
11. Porras AG, Holland SD, Gertz BJ 1999 Pharmacokinetics of alendronate. Clin Pharmacokinet 36:315-328.
12. Tonino RP, Meunier PJ, Emkey R, Rodriguez-Portales JA, Menkes CJ, Wasnich RD, Bone HG, Santora AC, Wu M, Desai R, Ross PD 2000 Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab 85:3109-3115.
13. McClung M, Miller P, Civitelli R, Warren M, Greenspan S, Haddock L, Tamayo J, Donley D, San Martin J 2003 Differential effects of teriparatide and alendronate on markers of bone remodeling and areal and volumetric bone density in women with osteoporosis. J Bone Miner Res 18:S2;S40.
14. Ma YL, Bryant HU, Zeng Q, Schmidt A, Hoover J, Cole HW, Yao W, Jee WS, Sato M 2003 New bone formation with teriparatide [human parathyroid hormone-(1-34)] is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats. Endocrinology 144:2008-2015.
15. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637-645.
16. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC 1999 Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 104:439-446.
17. Dobnig H, Turner RT 1995 Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 136:3632-3638.
18. Onyia JE, Bidwell J, Herring J, Hulman J, Hock JM 1995 In vivo, human parathyroid hormone fragment (hPTH 1-34) transiently stimulates immediate early response gene expression, but not proliferation, in trabecular bone cells of young rats. Bone 17:479-484.
19. Ott SM, Oleksik A, Lu Y, Harper K, Lips P 2002 Bone histomorphometric and biochemical marker results of a 2-year placebo-controlled trial of raloxifene in postmenopausal women. J Bone Miner Res 17:341-348.
20. Finkelstein JS, Klibanski A, Arnold AL, Toth TL, Hornstein M, Neer RM 1998 Prevention of estrogen deficiency-related bone loss with human parathyroid hormone (1-34): A randomized controlled trial. JAMA 280:1067-1073.
21. Hodsman AB, Hanley DA, Ettinger MP, Bolognese MA, Fox J, Metcalfe AJ, Lindsay R 2003 Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 88:5212-5220.
22. Parfitt AM 1983 The physiological and clinical significance of bone histomorphometric data. In: Recker R (ed.) Bone Histomorphometry: Techniques and Interpretations. CRC Press, Boca Raton, FL, USA, pp. 143-223.
23. Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ 2000 Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27:687-694.
24. Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, Rosen CJ 2000 Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 85:2129-2134.
25. Parfitt AM 1980 Morphologic basis of bone mineral measurements: Transient and steady state effects of treatment in osteoporosis. Miner Electrolyte Metab 4:273-287.
26. Frost HM 1989 Some effects of basic multicellular unit-based remodelling on photon absorptiometry of trabecular bone. Bone Miner 7:47-65.
27. Marcus R, Wang O, Satterwhite J, Mitlak B 2003 The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 18:18-23.